Audentes Therapeutics, Inc
BOLD
BOLD was delisted on the 14th of January, 2020.
49 hedge funds and large institutions have $272M invested in Audentes Therapeutics, Inc in 2016 Q3 according to their latest regulatory filings, with 49 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$72.9M |
| 2 |
VVM
Versant Venture Management
San Francisco,
California
|
+$27.4M |
| 3 |
DM
Deerfield Management
New York
|
+$21.3M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
+$13.9M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$10.7M |
Top Sellers
BOLD Hedge Fund Activity: Q3 2016 in Review
49 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Audentes Therapeutics, Inc (BOLD) for Q3 2016, worth a combined $272M.
Buyers outnumbered sellers: 49 funds opened new BOLD positions and 0 closed out — a net gain of 49 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $72.9M.
- 49 institutional investors held Audentes Therapeutics, Inc (BOLD) as of Q3 2016, up from 0 in Q2 2016.
- Funds reported $272M of Audentes Therapeutics, Inc stock for Q3 2016.
- 49 funds opened new Audentes Therapeutics, Inc positions in Q3 2016 and 0 closed out, a net change of +49 holders.
- The largest Audentes Therapeutics, Inc buyer in Q3 2016 was OrbiMed, an estimated $72.9M added.
Based on aggregated 13F filings for Q3 2016.